Mirati, Sanofi join forces in lung cancer with a KRAS-SHP2 combo approach

Mirati may have been beaten to the punch by Amgen after it nabbed a speedy FDA approval for its KRAS drug Lumakras this year, but it’s still pushing to try to wring the most efficacy out of its rival therapy.